Despite the lingering macroeconomic headwinds, mergers and acquisitions in the biotech industry are getting back to normal levels as larger companies are making acquisitions to realize their growth plans and gain access to innovative technologies. Moreover, telehealth, health tech, and analytics companies will likely continue to boost growth in the sector.
The biotechnology market is driven by strong government support aimed at the modernization of the regulatory framework, improvements in approval processes & reimbursement policies, and standardization of clinical studies.
